Technical Data on Biotech Stocks -- Research on Alexion Pharma, Incyte, Merrimack Pharma, and Aastrom Biosciences
PR Newswire - Mon Apr 14, 8:00AM CDT
On Friday, April 11, 2014, the NASDAQ Composite ended at 3,999.73, down 1.34%, the Dow Jones Industrial Average declined 0.89% to 16,026.75, and the S&P 500 closed at 1,815.69, down 0.95%. The losses were broad based as all the 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 644.74, down 1.07%, and the same has lost 4.46% in the last one month. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Incyte Corp. Ltd (NASDAQ: INCY), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) and Aastrom Biosciences Inc. (NASDAQ: ASTM). Free technical research on ALXN, INCY, MACK and ASTM can be downloaded upon signing up at:
2 Biotech Stocks to Watch: Merrimack Pharmaceuticals and Sunesis Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Apr 10, 5:30PM CDT
Although 2014 has gotten off to a rocky start for biotechs, a fair number of companies have exploded higher after reporting positive clinical trial data. For example, Endocyte doubled in a day after unveiling positive data for its experimental...
Merrimack Announces Preliminary Data From Pilot Diagnostic Imaging Study of MM-398
GlobeNewswire - Tue Apr 08, 8:39AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced Phase 1 results from a clinical pilot study demonstrating that ferumoxytol*, an iron oxide nanoparticle, was well tolerated when used as a tumor contrast agent prior to MM-398 treatment. Data from the first cohort of patients in this study were presented at the American Association of Cancer Research Annual Meeting, April 5-9, 2014, in San Diego, California.
Merrimack to Present at the 2014 American Association for Cancer Research Annual Meeting
GlobeNewswire - Mon Mar 31, 7:12AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present at the 2014 AACR Annual Meeting. The conference will take place on April 5-9, 2014 at the San Diego Convention Center in San Diego. Presentations will include a clinical pilot study evaluating the feasibility of using ferumoxytol as an MRI imaging agent prior to MM-398 investigational treatment. Additional preclinical presentations describe the relationship between ferumoxytol and MM-398 tumor uptake and activity, as well as exploring the mechanistic basis of MM-398 activity across multiple tumor models. Data will be presented in four poster sessions.
Pre-market Biotech Picks -- Research on Merrimack Pharma, Alexion Pharma, Incyte, and Aastrom Biosciences
PR Newswire - Tue Mar 25, 10:25AM CDT
On Monday, March 24, 2014, the NASDAQ Composite ended at 4,226.39, down 1.18%, the Dow Jones Industrial Average declined 0.16% to 16,276.69, and the S&P 500 closed at 1,857.44, down 0.49%. The losses were broad based as 8 out of 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41%, and the same has fallen by 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Incyte Corp. Ltd (NASDAQ: INCY) and Aastrom Biosciences Inc. (NASDAQ: ASTM). Free technical research on MACK, ALXN, INCY and ASTM can be downloaded upon signing up at:
Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors
M2 - Fri Mar 14, 4:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvnwqx/competitor) has announced the addition of the "Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors" report to their offering. The present Competitive Intelligence Report about EGF-R Antibodies -Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. At present, there are two approved and marketed EGF-R antibodies in regulated markets which posted combined 2013 sales of US$ 2,486 mln. A third EGF-R antibody is approved in a number of less regulated markets. Among the approved indications for use of EGF-R antibodies are K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). Further indications are under clinical evaluation. The attractive market size and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies. The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered 1. EGF-R Antibodies -Biosimilars and Biosuperiors Marketed EGF-R Antibodies - Erbitux Sales & Pipeline - Vectibix Sales & Pipeline - Nimotuzumab Pipeline EGF-R Antibody Biobetters/Biosuperiors - Engineered EGF-R Antibodies - Bi- and Multispecific EGF-R Antibodies - EGF-R Antibody-Drug Conjugates EGF-R Antibody Biosimilars - Cetuximab Biosimilars - Panitumumab Biosimilars 2. Corporate EGF-R Antibody Biosimilar & Biobetter Pipelines Companies Mentioned - AbbVie - Actavis - Amgen - Avesthagen Pharma - Biocon - BioXpress - Bristol-Myers Squibb (BMS) - Celltrion - Centro de Imunologica Molecular AB (CIMAB) - CytomX Therapeutics - Daiichi Sankyo - Eli Lilly - Fusion Therapeutics - Glycotope - Green Cross - Hospira - Immune Pharmaceuticals - Immunogen - Innogene Kalbiotech - InnoMab - ISU Abxis - Janssen Pharmaceuticals - Med Discover - Merck GKaA - Merrimack Pharmaceuticals - Merus - Oncobiologics - Oncoscience - Pfizer 4 - PharmaPraxis - PlantForm - Roche - Shanghai Zhangjiang Biotechnology - Sorrento Therapeutics - Symphogen - Takeda Pharmaceutical - Viropro - Zyngenia For more information visit http://www.researchandmarkets.com/research/vvnwqx/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics
PR Newswire - Thu Mar 13, 7:20AM CDT
Today, Analysts Review released its analysts' notes regarding Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Rosetta Genomics, Ltd. (NASDAQ: ROSG), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Should You Worry About the Short Interest in Merrimack (MACK)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 9:33AM CST
Should You Worry About the Short Interest in Merrimack (MACK)?
Merrimack Provides Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Feb 27, 3:14PM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer, today announced its fourth quarter and full year 2013 financial results.
Today's Biggest Stories in Biotech: Galectin Therapeutics Inc, Merrimack Pharmaceuticals and Nektar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 27, 8:27AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Study Shows Mentally Ill More Likely To Be Victims, Not Perpetrators, Of Violence
M2 - Tue Feb 25, 8:49AM CST
Merrimack to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Mon Feb 24, 7:00AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Ulrik Nielsen, Chief Scientific Officer, is scheduled to present at the Cowen and Company 34 Annual Health Care Conference on Monday, March 3, 2014 at 4:50 p.m. (ET) at the Boston Marriott Copley Place in Boston.
Merrimack Announces Timing of Fourth Quarter 2013 Investor Conference Call
GlobeNewswire - Thu Feb 20, 3:20PM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Fourth Quarter 2013 Investor Conference Call and webcast at 4:30 p.m., Eastern time, on Thursday, February 27.
3 Small Cap Biotechs Developing Novel Cancer Treatments
George Budwell, The Motley Fool - Motley Fool - Tue Feb 18, 1:30PM CST
Cancer drugs can be game-changers for their developers because of their comparatively high margins and their tendency to be applicable to a broad array of disease states. In short, Foolish investors would be wise to keep an eye out for companies...
Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics
GlobeNewswire - Tue Feb 18, 7:01AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the manuscript "MM-141, an IGF-1R- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-1R Inhibitors" has been published in Molecular Cancer Therapeutics and selected for the Highlights section in the current issue (Volume 13, Issue 2).
Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 14, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/d9hf73/gastroesophageal) has announced the addition of the "Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2013" report to their offering. 'Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas. Scope - A snapshot of the global therapeutic scenario for Gastroesophageal (GE) Junction Carcinomas. - A review of the Gastroesophageal (GE) Junction Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gastroesophageal (GE) Junction Carcinomas pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Gastroesophageal (GE) Junction Carcinomas Overview Therapeutics Development Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Overview Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis Gastroesophageal (GE) Junction Carcinomas - Therapeutics under Development by Companies Gastroesophageal (GE) Junction Carcinomas - Pipeline Products Glance Late Stage Products Clinical Stage Products Gastroesophageal (GE) Junction Carcinomas - Products under Development by Companies Gastroesophageal (GE) Junction Carcinomas - Companies Involved in Therapeutics Development Gastroesophageal (GE) Junction Carcinomas - Therapeutics Assessment Drug Profiles pertuzumab - Drug Profile onartuzumab - Drug Profile olaparib - Drug Profile ipilimumab - Drug Profile trebananib - Drug Profile alisertib - Drug Profile varlitinib - Drug Profile MM-111 - Drug Profile MEDI-4736 - Drug Profile R&D Progress Featured News & Press Releases Appendix Companies Mentioned Bristol-Myers Squibb Company F. Hoffmann-La Roche Ltd. Amgen Inc. AstraZeneca PLC MedImmune, LLC Millennium Pharmaceuticals, Inc. Merrimack Pharmaceuticals, Inc. Aslan Pharmaceuticals Pte. Ltd. For more information visit http://www.researchandmarkets.com/research/d9...esophageal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Monoclonal Antibodies Market in Breast Cancer to 2019: Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth
M2 - Thu Feb 13, 10:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/3fr5l8/monoclonal) has announced the addition of the "Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth" report to their offering. The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein. Four are aimed at improving overall survival in the metastatic setting, and two of these have also received further approvals in the early setting in order to improve long-term remission rates. The market is currently led by the HER-2 inhibitor Herceptin, which achieved global sales amounting to $6.2 billion in 2012. Over the forecast period from 2012 to 2019, the two novel HER-2 inhibitors, Kadcyla and Perjeta, are expected to achieve strong market penetration due to their appreciable incremental efficacy benefits. Additionally, the market conditions are currently favorable towards mAbs, with a low rate of price depreciation following patent expiry and a high rate of inflation for specialty pharmaceuticals in the US. As a result of this, and despite the empty Phase III pipeline, the authors believe that the global market across the leading eight countries have the potential to grow to a value of $10.6 billion by 2019. Key Topics Covered: 1. Tables & Figures 2 Introduction 3 Marketed Products 3.1 Herceptin (Trastuzumab) - Hoffmann La Roche 3.2 Avastin (Bevacizumab) - Hoffmann La Roche 3.3 Kadcyla (Trastuzumab Emtansine) - Hoffmann La Roche 3.4 Perjeta (Pertuzumab) - Hoffmann La Roche 3.5 Xgeva (denosumab) - Amgen 3.6 Heat Map for Marketed Products 3.7 Conclusion 4 Pipeline for Breast Cancer Monoclonal Antibody Therapeutics 4.1 Overall Pipeline 4.2 Mechanisms of Action 4.3 Clinical Trials 4.3.1 Attrition Rate 4.3.2 Clinical Trial Size 4.3.3 Duration 4.3.4 Clinical Trial End-points 4.4 Promising Drug Candidates in the Pipeline 4.4.1 CDX-011 (glembatumumab vedotin) - Celldex Therapeutics 4.4.2 Metmab (onartuzumab) - Hoffman La Roche 4.4.3 Hu3S193 - Recepta Biopharma 4.4.4 MM-121 - Merrimack Pharmaceuticals 4.4.5 IMC-18F1 (Icrucumab) - Eli Lilly 4.4.6 Rexomun (Ertumaxomab) - Fresenius Biotech 4.4.7 Medi-573 (Dusigitumab) - Medimmune 4.4.8 MK-0646 (Dalotuzumab) - Merck and Co 4.4.9 LY3012217 (Cixutumumab) - Eli Lilly 4.5 Conclusion 5 Market Forecast to 2019 5.1 Global 5.2 US 5.3 Canada 5.4 Europe 5.5 Japan 5.6 Drivers and Barriers 6 Deals and Strategic Consolidations 7 Appendix For more information visit http://www.researchandmarkets.com/research/3fr5l8/monoclonal
Nasdaq stocks posting largest percentage decreases
AP - Mon Jan 27, 12:28PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Merrimack Initiates Phase 1 Clinical Study of MM-398 in Combination With Cyclophosphamide for Pediatric Solid Tumors
GlobeNewswire - Thu Jan 23, 7:00AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a Phase 1 dose-escalating clinical study of MM-398 in conjunction with cyclophosphamide for the treatment of pediatric solid tumors. MM-398 is a stable nanoliposomal irinotecan that is designed to exploit leaky tumor vasculature for enhanced drug delivery to tumors.
3 New Cancer Treatments to Watch in 2014
Leo Sun, The Motley Fool - Motley Fool - Wed Jan 22, 5:31PM CST
Follow @leokornsun // full story)